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Abstract
Background—Harmane (1-methyl-9H-pyrido[3,4-b]indole), a neurotoxin, may be an
environmental risk factor for essential tremor (ET). Harmane and related chemicals are toxic to the
cerebellum. Whether it is through this mechanism (cerebellar toxicity) that harmane leads to ET is
unknown. Impaired olfaction may be a feature of cerebellar disease.
Objective—To determine whether blood harmane concentrations correlate with olfactory test
scores in patients with ET.
Methods—Blood harmane concentrations were quantified using high performance liquid
chromatography. Odor identification testing was performed with the University of Pennsylvania
Smell Identification Test (UPSIT).
Results—In 83 ET cases, higher log blood harmane concentration was correlated with lower UPSIT
score (rho = !0.46, p < 0.001). 25/40 (62.5%) cases with high log blood harmane concentration
(based on a median split) had low UPSIT scores (based on a median split) vs. 12/43 (27.9%) ET
cases with low log blood harmane concentration (adjusted OR 4.04, 95% CI 1.42 – 11.50, p = 0.009).
When compared with the low log blood harmane tertile, the odds of olfactory dysfunction were 2.64
times higher in cases in the middle tertile and 10.95 times higher in cases in the high tertile. In 69
control subjects, higher log blood harmane concentration was not correlated with lower UPSIT score
(rho = 0.12, p = 0.32).
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Conclusions—Blood harmane concentrations were correlated with UPSIT scores in ET cases but
not controls. These analyses set the stage for postmortem studies to further explore the role of harmane
as a cerebellar toxin in ET.
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Introduction
Essential tremor (ET), characterized by action tremor of the hands, is a widespread late-life
neurological disease that is present in 4.0% of individuals aged " 40 years and 8.7% in
individuals in their ninth decade (Benito-Leon et al., 2003; Dogu et al., 2003). It is one of the
most prevalent neurological disorders (Benito-Leon et al., 2003; Dogu et al., 2003). Aside from
action tremor, ET patients exhibit other signs, including cognitive impairment (Benito-Leon
et al., 2006), and gait ataxia and incoordination (Singer et al., 1994). Treatment options are
limited (Zesiewicz et al., 2005).
The pathophysiology of ET is not well-understood, but clinical (Singer et al., 1994) and
imaging (Bucher et al., 1997; Jenkins et al., 1993; Pagan et al., 2003) studies have demonstrated
cerebellar abnormalities and pathological studies have recently revealed several features of
cerebellar degeneration in many ET cases (Louis et al., 2007a; Louis et al., 2006; Shill H,
2007).
Harmane (1-methyl-9H-pyrido[3,4-b]indole) and other dietary #-carboline alkaloids are potent
tremor-producing neurotoxins (McKenna, 1996; Zetler et al., 1972). These alkaloids, including
harmane, are present in a variety of foods (especially meats but also in plant-derived foods
[e.g., coffee, flour, cocao, tomatoes]) (Herraiz, 2004; Pfau and Skog, 2004). #-carboline
alkaloids can produce marked cerebellar damage in exposed laboratory animals (Milner et al.,
1995; O'Hearn and Molliver, 1997). Interestingly, higher blood harmane concentrations have
been reported in ET patients compared to controls (Louis et al., 2005; Louis et al., 2002b),
raising the possibility that harmane is an environmental/dietary risk factor for ET. Moreover,
in ET patients, higher blood harmane concentrations have been correlated with evidence of
impaired cerebellar metabolism in a magnetic resonance spectroscopic imaging study (Louis
et al., 2007b), suggesting that harmane may perhaps be acting as a cerebellar toxin in patients
with ET. However, this has not been definitively established.
Olfactory dysfunction occurs in a number of neurological diseases (Doty et al., 1988; Doty et
al., 1987). Olfaction is mildly impaired in several studies of ET in which patients exhibit lower
University of Pennsylvania Smell Identification Test (UPSIT) scores (Applegate and Louis,
2005; Louis et al., 2002a; Louis and Jurewicz, 2003). Olfactory dysfunction occurs in patients
with cerebellar diseases (Connelly et al., 2003; Velazquez-Perez et al., 2006) and there is
considerable evidence that the cerebellum itself may play a role in central olfactory processing
(Connelly et al., 2003; Deiss and Baudoin, 1997; Sobel et al., 1998; Velazquez-Perez et al.,
2006).
To further test the model that harmane, through cerebellar toxicity, leads to ET, we
hypothesized that we would find a correlation between blood harmane concentrations and
UPSIT scores in ET cases and furthermore, that such a correlation would not be detected among
a group of controls. Our overarching goal in this study was to further explore the emerging
links between this dietary neurotoxin and ET.
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Recruitment began in July, 2000 and has continued to present (September, 2007). All ET cases
were enrolled in a study of the environmental epidemiology of ET at Columbia-University
Medical Center (CUMC). ET cases were identified from two sources: (1) a computerized
billing database at CUMC, and (2) advertisements to members of the International Essential
Tremor Foundation. All cases had received a diagnosis of ET from their treating neurologist
and all lived within two hours driving distance of CUMC in New York, New Jersey, and
Connecticut. The office records of all identified patients were reviewed and patients with
diagnoses or physical signs of dystonia, Parkinson’s disease (PD), or spinocerebellar ataxia
were excluded. Control subjects were recruited during the same time period. Controls were
identified using random digit telephone dialing within a defined set of telephone area codes
that were represented by the cases (e.g., 212, 201, 203, 516, 718, 914) within the New York
Metropolitan area. Controls were frequency-matched to cases based on gender, race (White,
African-American, Hispanic, Asian, Other), and current age (5 year intervals). The CUMC
Internal Review Board approved of all study procedures and written informed consent was
obtained at the time of enrollment.
ET cases and controls were screened for cognitive impairment using the 10-minute Telephone
Interview for Cognitive Status (Brandt J, 1988). This was done to minimize the enrollment of
individuals with dementia and, therefore, potentially invalid medical histories. Eight
individuals (one case and seven controls) with cognitive impairment (score < 30 of 41) were
excluded prior to enrollment.
Clinical Evaluation
All case and control subjects were evaluated in person by a trained tester who administered
clinical questionnaires and performed a videotaped examination. Most evaluations were
performed in the late morning or early afternoon, making fasting levels impractical. Data
suggest that plasma concentrations of harmane do not change significantly during the day
(Rommelspacher et al., 1991). In one study (Rommelspacher et al., 1991), human subjects
ingested food or ethanol, and plasma harmane concentrations were measured hourly for eight
hours. The concentration remained stable. The same investigators also demonstrated that
variability in concentration was minimal over a longer (three week) period (Rommelspacher
et al., 1991). Our own data indicate that log blood harmane concentration is not correlated with
the time latency since last food consumption (rho = !0.097, p = 0.49 [52 subjects]).
The tester collected demographic information (age in years, gender, race [non-Hispanic white
vs. others], years of education, number of rooms in home) and clinical information (tremor
duration in years, years since last hospitalization, tobacco use including current cigarette
smoking, names and dosages of all current medications). Medical co-morbidity was assessed
with the Cumulative Illness Rating Scale, in which the severity of medical problems (0 [none]
- 3 [severe]) was rated in 14 bodily systems and a Cumulative Illness Rating Scale score was
assigned (range = 0 – 42) to each subject (Linn et al., 1968).
The tester videotaped a tremor examination in all subjects (Louis et al., 1997; Louis et al.,
2002b), and each of 12 videotaped action tremor items was rated by Dr. Louis on a scale from
0 to 3, resulting in a total tremor score (range = 0 – 36 [maximum]). The diagnosis of ET was
confirmed by Dr. Louis using published diagnostic criteria (moderate or greater amplitude
tremor during three activities or a head tremor in the absence of PD, dystonia or another
neurological disorder)(Louis et al., 1998a; Louis et al., 1997; Louis et al., 2002b). None of the
final sample of 83 ET cases or 69 control subjects had PD or dystonia.
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During the clinical evaluation, phlebotomy was performed. Blood concentrations of harmane
were measured blinded to any clinical information. Harmane concentrations in blood were
quantified by a well-established high performance liquid chromatography (HPLC) method in
this group in our previous studies (Zheng et al., 2000). Briefly, one volume (9 – 12 ml) of
whole blood was digested with NaOH, extracted with ethyl acetate and methyl-t-butyl ether
(2:98, V:V), and reconstructed in methanol. Harmane was separated and quantified by HPLC
with a fluorescence detector at an excitation wavelength of 300 nm and an emission wavelength
of 435 nm. The intraday precision, measured as a coefficient of variation at 25 ng/ml, was
6.7%. The interday precision was 7.3% (Guan et al., 2001; Zheng et al., 2000).
Olfactory Testing
Odor identification testing was performed with the UPSIT (Sensonics Inc., Haddon Heights
NJ) in which 40 microencapsulated odors were presented using a four-item forced choice word
format (Doty et al., 1988; Doty et al., 1992). Testing was not performed if participants had
active upper respiratory tract infections or allergies or were current smokers. ET cases with
tremor that was severe enough to compromise their ability to scratch the odor panel or hold it
to their nose were assisted by the tester, although this was an extremely rare occurrence. The
UPSIT is highly reliable and sensitive to a variety of olfactory deficits. The scores range from
0 to 40 (all odors correctly identified)(Doty et al., 1988; Doty et al., 1992). UPSIT percentiles
are based on age and gender norms (Doty et al., 1988; Doty et al., 1992).
Final Sample
509 subjects were enrolled in the study of blood harmane concentration. Of these, 101 (19.8%)
did not have their blood drawn (e.g., refused or failed phlebotomy) and 12 (2.4%) had
phlebotomy but the quantity of blood was not sufficient. Thirty-five current cigarette smokers
were excluded because smoking is associated with a lower UPSIT score (Frye et al., 1990). Of
the remaining 361 subjects, 152 (83 cases and 69 controls) were enrolled after the
administration of the UPSIT had been added to the study protocol. We compared the base
sample (509 subjects) to the final sample (152 subjects used in these analyses), and they were
similar in terms of gender (274 [53.8%] vs. 76 [50.0%] women, chi-square [$2] = 0.69, p =
0.41), years of education (15.2 ± 3.6 years vs. 15.6 ± 3.5 years, t = 1.21, p = 0.23), and race
(463 [91.0%] vs. 140 [92.1%] white, $2 = 0.19, p = 0.66) but on average were 2.7 years older
(66.3 ± 14.4 years vs. 63.6 ± 14.2 years, t = 2.03, p = 0.04).
Statistical Analyses
Statistical analyses were performed in SPSS (Version 13.0). We used the published formula
(41 - UPSIT), suggested for analysis of UPSIT data (Frye et al., 1990). This score was then
log transformed to better normalize the distribution: log (41 – UPSIT). All analyses were
performed with UPSIT scores and log transformed scores; we presented the results of the
former, which lend themselves to comparisons with other published studies. The empirical
distribution of harmane was also skewed; therefore harmane concentrations were
logarithmically transformed.
We used Student’s t tests and $2 tests to compare cases and controls. Pearson’s rho (normally
distributed variables) and Spearman’s rho (non-normal distribution) were used to test for
correlations. Mann Whitney test was used to test for group differences in UPSIT scores.
Our main analyses were stratified by diagnosis (ET cases, controls). In linear regression
analyses, UPSIT score was the dependent variable and log blood harmane concentration was
the main independent variable. We considered a number of potential confounders (age in years,
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gender, race, years of education, Cumulative Illness Rating scale score, number of rooms in
home, and years since last hospitalization), and included these in the adjusted regression
analyses if they were associated with either log blood harmane concentration or UPSIT score.
In ET cases, log blood harmane concentration and UPSIT scores were stratified into high and
low values based on median values. In logistic regression analyses, UPSIT score (low vs. high,
based on the median split) was the dependent variable and log blood harmane concentration
(low vs. high, based on the median split) was the main independent variable. In other analyses,
log blood harmane concentration was also stratified into tertiles. In logistic regression analyses,
UPSIT score (low vs. high) was the dependent variable and log blood harmane concentration
tertiles were the independent variables; we calculated odds ratios (OR) with 95% Confidence
Intervals (CI), comparing the middle and highest tertiles to the lowest (reference) tertile. To
test for trend, in a linear regression analysis, UPSIT score was the dependent variable and log
blood harmane concentration tertile was the independent variable.
Results
Cases and Controls
The 83 ET cases and 69 controls were similar in terms of demographic characteristics (Table
1). ET cases had a mean ± standard deviation (SD) tremor duration of 20.7 ± 16.4 years, a
mean total tremor score of 18.1 ± 6.9, and 30 (36.1%) were taking daily medication to treat
their tremor. In the current sample, the transformed UPSIT score was marginally higher and
UPSIT percentile was marginally lower (i.e., marginally greater olfactory dysfunction) in ET
cases than in controls. Log blood harmane concentration was higher in ET cases than controls
(Table 1).
Using our control sample, we examined the correlates of UPSIT score. Lower UPSIT score
(i.e., greater olfactory dysfunction) was associated with older age (rho = !0.45, p < 0.001),
fewer years of education (rho = 0.28, p = 0.02), and marginally with higher Cumulative Illness
Rating Scale score (rho = !0.19, p = 0.12). It was not associated with years since last
hospitalization (rho = 0.17, p = 0.35), number of rooms in home (rho = 0.11, p = 0.37) or race.
There was a marginal association with gender (median = 32 in men and 34 in women, Mann
Whitney z = 1.42, p = 0.16). In controls, log blood harmane concentration was not associated
with age (rho = 0.03, p = 0.79), years of education (rho = 0.10, p = 0.40), Cumulative Illness
Rating Scale score (rho = !0.12, p = 0.32), number of rooms in home (rho = 0.06, p = 0.65),
years since last hospitalization (rho = !0.10, p = 0.45), gender (0.37 ± 0.51 g!10/ml in men and
0.28 ± 0.70 g!10/ml in women, t = 0.65, p = 0.52), or race.
Analyses in ET Cases
In ET cases, higher log blood harmane concentration was correlated with lower UPSIT score
(rho = !0.46, p < 0.001, Figure 1). Even among 28 cases with ET of shorter tremor duration
(< 10 years, mean ± SD = 5.4 ± 2.6 years), the correlation was robust (rho = !0.59, p = 0.001).
In a linear regression analysis, higher log blood harmane concentration was associated with
lower UPSIT score (dependent variable) after adjusting for age in years, gender, years of
education, and Cumulative Illness Rating Scale score (beta = !3.41, p = 0.001).
Log blood harmane concentration and UPSIT scores were stratified into high versus low values
based on the medians. Twenty-five (62.5%) of 40 ET cases with high log blood harmane
concentration had low UPSIT scores vs. 12 (27.9%) of 43 ET cases with low log blood harmane
concentration (OR = 4.31, 95% CI = 1.71 – 10.85, p = 0.002, i.e., the odds of having olfactory
dysfunction were four times higher among ET cases with high log blood harmane concentration
than ET cases with low log blood harmane concentration). After adjusting for age in years,
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gender, years of education, and Cumulative Illness Rating Scale score in a logistic regression
analysis, results were similar (OR = 4.04, 95% CI = 1.42 – 11.50, p = 0.009).
Log blood harmane concentration was also stratified into tertiles. The mean ± SD UPSIT score
in the low log blood harmane tertile = 32.9 ± 3.1, in the middle tertile = 31.1 ± 4.9, and in the
high tertile = 27.3 ± 6.0 (difference between low and high tertile = 5.6 UPSIT points, and in a
test for trend [linear regression model], p < 0.001)(Figure 2). When compared with the low
(reference) log blood harmane tertile, the odds of olfactory dysfunction (based on a median
split) were 2.64 times higher in cases in the middle tertile and 10.95 times higher in cases in
the high tertile (Table 2). These odds were higher in a logistic regression analysis that adjusted
for age in years, gender, years of education, and Cumulative Illness Rating Scale score (Table
2).
Analyses in Controls
In controls, higher log blood harmane concentration was not correlated with lower UPSIT score
(rho = 0.12, p = 0.32)(Figure 3). In a linear regression analysis, higher log blood harmane
concentration was not associated with lower UPSIT score (dependent variable) after adjusting
for age in years, gender, years of education, and Cumulative Illness Rating Scale score (beta
= 0.74, p = 0.48).
Discussion
Higher blood harmane concentrations were correlated with lower olfactory test scores. The
association was specific to ET cases and was not observed in controls. Harmane is an
environmental toxin with potent tremor-producing properties (McKenna, 1996; Zetler et al.,
1972). Harmane and other members of its chemical class (e.g., harmaline, harmine and other
#-carboline alkaloids) are highly neurotoxic; and it has been known for more than 100 years
that administration of these chemicals to a wide variety of laboratory animals produces an
intense and generalized action tremor resembling ET (Du et al., 1997). The harmaline model
is the traditional animal model for ET and new therapies are tested using exposed animals
(Martin et al., 2005). #-carboline alkaloids, and especially harmane, are present in a variety of
foods (especially protein-rich foods such as meat but also in plants) and certain cooking
practices (e.g., char-broiling) increase the concentrations of these chemicals (Herraiz, 2004;
Pfau and Skog, 2004). Once they are ingested and enter the systemic circulation, these
chemicals cross the blood brain barrier through an active uptake mechanism and, although
related, brain concentrations are higher than those seen in the blood (Anderson et al., 2006;
Guan et al., 2001). Some members of this class of chemicals are able to produce toxic damage
with marked destruction of cerebellar Purkinje cells (O'Hearn and Molliver, 1997).
Higher blood harmane concentrations have been observed in ET patients in case-control studies
(Louis ED, 2008 In Press; Louis et al., 2005; Louis et al., 2002b), raising the possibility that
this environmental-dietary toxin is a risk factor for ET. In one recent study of ET patients,
higher blood harmane concentrations correlated strongly with metabolic evidence of cerebellar
damage on magnetic resonance spectroscopic imaging (Louis et al., 2007b) This finding, of
increased blood harmane concentration associated with greater cerebellar neuronal damage, is
consistent with the animal study data that #-carboline alkaloids appear to be neurotoxic to the
cerebellum (Milner et al., 1995; O'Hearn and Molliver, 1997). We have furthermore shown in
the present analyses that blood harmane concentrations are associated with olfactory test
scores, which themselves may be another measure of cerebellar dysfunction in ET. Indeed, in
the present set of analyses, we found that higher blood harmane concentrations were correlated
with lower UPSIT scores among ET cases but not in controls. Postmortem studies are now
needed to more directly address the relationship between this toxin and the cerebellum in
patients with ET. With postmortem tissue, one could directly assess whether cerebellar
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harmane concentration is elevated in ET case brains relative to control brains and whether
higher blood and cerebellar harmane concentrations are correlated with greater postmortem
changes in the cerebellum in ET. The current set of results provides further rationale for
conducting such a postmortem study.
Several types of evidence suggest that the cerebellum may be involved in olfactory processing.
First, there are reports of olfactory dysfunction in patients with cerebellar diseases (Connelly
et al., 2003; Mainland et al., 2005; Tucker, 1911; Velazquez-Perez et al., 2006). Second, the
staggerer mouse, which has abnormalities in the olivocerebellar pathway, is hyposmic (Deiss
and Baudoin, 1997; Deiss and Baudoin, 1999). Third, recent functional magnetic resonance
imaging and positron emission tomography studies show marked odor-induced cerebellar
activity (Ferdon and Murphy, 2003; Qureshy et al., 2000; Sobel et al., 1998; Yousem et al.,
1997).
In the present sample, olfactory test scores were marginally lower in ET cases than in controls.
In our previous studies (Applegate and Louis, 2005; Louis et al., 2002a; Louis and Jurewicz,
2003), the case-control difference was slightly greater, and this might reflect sampling
differences between studies.
This study had limitations. First, our final sample of 152 subjects was 2.7 years younger on
average than the base sample of 509; however, our data indicate that blood harmane
concentration was not associated with age, so this should not have influenced our findings.
Second, fasting blood harmane levels were impractical in this study. However, data, including
our own, suggest that plasma concentrations of harmane do not change significantly during the
day (Rommelspacher et al., 1991). Finally, we did not collect data on reported (i.e.,
symptomatic) olfactory dysfunction. The strengths of this study include the uniqueness of the
question (to our knowledge, no other studies have examined this issue), the collection of both
UPSIT and blood harmane concentration data in the same study subjects, collection of data in
both cases and a comparison group of controls, and as part of a larger epidemiological study
we had the ability to adjust for multiple potential confounding factors.
ET is the most common cause of tremor in humans, affecting large numbers of individuals in
every human population, with an estimated 13 million affected individuals in the United States
alone (Dogu et al., 2003; Louis et al., 1998b). There is a non-genetic component to the etiology
of ET that most likely represents the effects of environmental toxicants and that accounts for
a significant proportion of the incidence of this disease in the population (Fabrizio et al.,
2007; Jiménez-Jiménez FJ and B., 2007; Salemi et al., 1998). It is commonly stated that 50%
of ET cases are non-familial (Louis and Ottman, 1996). Given its population prevalence of
4.0% among persons age 40 and older (Dogu et al., 2003), then this suggests that approximately
2.0% of the population aged " 40 years has a non-familial form of ET (Dogu et al., 2003), yet
the environmental correlates for this tremor are just beginning to be explored. The role that the
neurotoxin harmane plays in the etiology of ET is not entirely clear, although our research is
suggesting that it likely to play a role (Guan et al., 2001; Louis et al., 2005; Louis et al.,
2002b; Louis et al., 2007b; Zheng et al., 2000). Further research to more rigorously study this
link and clarify its role will yield valuable information about the etiology of one of the most
commonly-occurring yet poorly-explored of the neurological diseases.
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Log blood harmane concentration (g!10/ml) was inversely associated with UPSIT score in ET
cases (rho = !0.46, p < 0.001). The fit line is also shown.
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Log blood harmane concentration was also stratified into tertiles in ET cases. The mean ± SD
UPSIT score in the low tertile = 32.9 ± 3.1, in the middle tertile = 31.1 ± 4.9, and in the high
tertile = 27.3 ± 6.0 (difference between low and high tertile = 5.6 UPSIT points, and in a test
for trend, beta = !2.79, p < 0.001). The bar represents two standard errors and the closed circle
represents the mean.
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Log blood harmane concentration (g!10/ml) was not associated with UPSIT score in controls
(rho = 0.12, p = 0.32). The fit line is also shown.
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Table 1
Demographic and clinical characteristics of study subjects
ET Cases (N = 83) Controls (N = 69)
Age in years 63.7 ± 13.7 63.5 ± 14.9
Female gender 38 (45.8%) 38 (55.1%)
White Race 78 (94.0%) 62 (89.9%)
Years of education 15.7 ± 3.6 15.5 ± 3.4
Cumulative Illness Rating Scale Score 5.0 ± 3.4 4.7 ± 3.8
Number of rooms in home 6.0 ± 2.6 6.3 ± 4.3
Years since last hospitalization 16.5 ± 21.7 16.3 ± 18.6
UPSIT score 30.5 ± 5.3 31.7 ± 5.5
Transformed UPSIT score 0.97 ± 0.22* 0.90 ± 0.24
UPSIT percentile 36.9 ± 24.7* 43.6 ± 24.2




p < 0.005 compared with controls.
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Table 2







Unadjusted OR, 95% CI,
p





   Low 6 (20.7%) 23 (79.3%) 1 (reference) 1 (reference)
   Middle 11 (40.7%) 16 (59.3%) 2.64 (0.81 – 8.59), 0.11 3.29 (0.85 – 12.78), 0.086
   High 20 (74.1%) 7 (25.9%) 10.95 (3.16 – 38.01),
<0.001
12.51 (2.83 – 55.23), 0.001
*
Olfactory dysfunction was based on a median split of UPSIT scores into low vs. high values.
Percentages are row percentages.
**
Adjusted for age in years, gender, years of education, and Cumulative Illness Rating Scale score in a logistic regression analysis.
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